Form 4: Centessa Pharmaceuticals CEO Saurabh Saha Sells Shares Under 10b5-1 Trading Plan

Centessa Pharmaceuticals' CEO, Saurabh Saha, sold 55,000 ordinary shares at an average price of $16.692 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 20, 2025, Saurabh Saha, CEO of Centessa Pharmaceuticals plc, sold 55,000 ordinary shares of the company.
• The sales were executed at a weighted average price of $16.692 per share.
• These transactions were carried out under a Rule 10b5-1 trading plan adopted on May 16, 2024.
• Following the reported transaction, Saha directly owns 276,017 ordinary shares and indirectly owns 38,000 shares through a trust.
• The shares sold were priced between $16.35 and $17.07.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine sale of shares by the CEO under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment, but the market reaction will depend on investor perception.

Industry Context

Sales by company insiders are a common occurrence, but investors often scrutinize them for signals about the company's prospects. Sales under a 10b5-1 plan are generally viewed as less concerning since they are pre-arranged.

Stakeholder Impact

• Shareholders may react to the news of the CEO's share sale, although the existence of a 10b5-1 plan may mitigate concerns.

Key Dates

Keywords

Centessa Pharmaceuticals, Saurabh Saha, share sale, Form 4, Rule 10b5-1, insider trading, CNTA